Viscosupplementation Market (By Product: Single Injection, Three Injection, Five Injection; By End-use: Hospitals, Orthopaedic Clinics/ASCs) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033


Viscosupplementation Market Size and Growth 2024 to 2033

The global viscosupplementation market size was valued at USD 4.84 billion in 2023 and is anticipated to reach around USD 12.10 billion by 2033, growing at a CAGR of 9.60% from 2024 to 2033. The rising geriatric population globally with increasing incidences of low bone density disorders due to the sedentary lifestyle and, therefore, the need for minimally invasive methods to resolve this are the major driving factors of the global viscosupplementation market.

Viscosupplementation Market Size 2024 to 2033

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Viscosupplementation Market Key Takeaways

  • Asia Pacific led the market with largest revenue share of 47% in 2023.
  • Europe is expected to witness notable growth in the foreseeable future.
  • By product, the three-injection segment has held the largest revenue share of 45% in 2023.
  • By product, the single injection segment is anticipated to showcase rising growth in the market over the forecasted years.
  • By end use, the orthopedic clinic/ASC segment has contributed more than 64% of revenue share of 64% in 2023.
  • By end use, the hospital segment is forecasted to grow rapidly in the market over the forecast period.

Asia Pacific Viscosupplementation Market Size and Growth 2024 to 2033

The Asia Pacific viscosupplementation market size was estimated at USD 2.27 billion in 2023 and is predicted to be worth around USD 5.75 billion by 2033 with a CAGR of 9.73% from 2024 to 2033.

Asia Pacific Viscosupplementation Market Size 2024 to 2033

Asia Pacific has emerged as the largest shareholder in the viscosupplementation market in 2023. The growth of the region is attributed to the increasing elderly population and rising concerns about a decrease in bone density leading towards osteoporosis and osteoarthritis, driving the market on a global level. Overall, the rising geriatric population and initiatives by prominent leaders are some of the major factors that help in driving the region in the viscosupplementation market. To tackle this concerning health issue, many initiatives are undertaken by various agencies that also aid in strengthening the market.

  • In April 2022, Kolen Life, along with Juniper Biologics, made an agreement to develop and commercialize the TissueGene-C low dose, which is an incubatory therapy for the treatment of knee osteoarthritis. It is administered in the market as a single intra-articular injection, which does not require surgical intervention.

Viscosupplementation Market Share, By Region, 2023 (%)

Europe is witnessing the fastest growth in the viscosupplementation market. The reason behind this expected future dominance is related to the increasing number of individuals dealing with osteoporosis in the region. To overcome this, major market players are investing in the market as it is poised to grow in the upcoming period, which will benefit them with a huge return.

  • According to the registered data, more than 2.5 million women in France and the UK are affected by osteoporosis solely.

In the viscosupplementation market, North America is expected to witness notable growth in the foreseeable future. It can generate a higher revenue share, and this growth is due to the acceptance of newly launched products to treat arthritis, especially by elderly individuals dealing with bone-related disorders. The rising incidence of sports injury, in particular ligament damage and knee injury, and the increased rate of traffic accidents are fuelling the demand for viscosupplementation therapy rather than surgical intervention. The accidental rate in the U.S. alone is significant, therefore increasing the innovative product demand to treat individuals dealing with bone-related disorders.

Europe Viscosupplementation Market Size and Growth 2024 to 2033

The Europe viscosupplementation market size was exhibited at USD 1.26 billion in 2023 and is projected to expand around USD 3.21 billion by 2033, poised to grow at a CAGR of 9.80% from 2024 to 2033.

Forecast Year Market Size in USD
2023 $ 1.26 Billion
2024 $ 1.38 Billion
2025 $ 1.51 Billion
2026 $ 1.66 Billion
2027 $ 1.81 Billion
2028 $ 1.99 Billion
2529 $ 2.18 Billion
2030 $ 2.39 Billion
2031 $ 2.62 Billion
2032 $ 2.87 Billion
2033 $ 3.21 Billion

 

Viscosupplementation Market Overview

In viscosupplementation treatment, an injection filled with hyaluronic acid is directly injected into the bloodstream within the area of the knee and joints, as this fluid plays a significant role in maintaining the necessary lubricant that is required for the easy function of joints. As this, fluid helps lower swelling or inflammation in arthritic joints, which relieves pain and stiffness within the affected area of the body, in particular, around the knee or hip joints. The viscosupplementation market involves the buisnesses involved in such procedures.

The global viscosupplementation market is growing rapidly, showcasing its importance in treating patients suffering from osteoarthritis and osteoporosis is generally seen in elderly people due to decreasing bone density as per age and overworking, which leads to the easy breakage of bones, susceptible to bone injury even by minor accidents, knee and joints pain or swelling due to the decreasing flexibility and strength of the cartilage.

The global geriatric population has risen prominently, and they are more vulnerable to hip and knee osteoarthritis, which again develops improper alignment between the anabolic and catabolic activity within the bone and joint structure. To overcome this health gradation, significant product launches and approvals play a crucial role in the viscosupplementation market.

Thus, the rising prevalence of bone diseases like osteoporosis, arthritis, lack of physical activities in any form, and a sedentary lifestyle, including insufficient vitamin D intake, surges the demand for treatment to resolve bone-related health issues with minimally invasive procedures by highly skilled professionals. These are some of the major driving factors that lead the viscosupplementation market further on a global scale.

Viscosupplementation Market Growth Factors

  • The global shift in the elderly demographic fuels the market majorly.
  • Development of new and improved hyaluronic acid formulations.
  • Growing inclination towards non-surgical interventions.
  • Advances in healthcare infrastructures and services with skilled professionals.
  • Favourable insurance and supportive reimbursement policies and frameworks.
  • Government initiatives for awareness programs for bone-related disorders and preventive care, including treatment options to mitigate the risks of fractures and accidents.

Viscosupplementation Market Scope

Report Coverage Details
Viscosupplementation Market Size in 2023 USD 4.84 Billion
Viscosupplementation Market Size in 2024 USD 5.30 Billion
Viscosupplementation Market Size by 2033 USD 12.10 Billion
Viscosupplementation Market Growth Rate CAGR of 9.60% from 2024 to 2033
Largest Market Asia Pacific
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Product, End-use, and Regions
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Viscosupplementation Market Dynamics

Driver: Non-surgical solutions

The major driver that aids the growth of the viscosupplementation market is a rising demand for non-surgical or minimally invasive methods and medications as they lower the risk of side effects or aftereffects of surgery. Thus, healthcare professionals and patients are seeking alternatives for invasive procedures such as hip replacement and joint replacement surgeries, which often lead to greater cost and longer recovery and sensitivity to the mobility of knees and overall bodily movements.

Viscosupplementation offers a spectrum of medicated solutions with non-invasive options that effectively manage osteoarthritis and its symptoms by injecting hyaluronic acid HA directly into the joints, which helps them to keep lubricated and providing cushion around it and making it safer than before, and less prone to breakage. Moreover, the in-demand viscosuplementes have demonstrated a clinical trial with a proven and long-term positive effect on knee osteoarthritis as the most efficient treatment. Also, the rising elderly population around the globe is again a major driving factor of the viscosupplementation market.

The rising geriatric population diagnosed with osteoarthritis and people's inclination towards minimally invasive or non-invasive medication alternatives, including healthcare reimbursement by government organizations, are the leading factors that help drive the viscosupplementation market on a global scale. Therefore, the demand for viscosupplementation is relatively higher among the geriatric population as it helps with joint pain, offers higher mobility and free movement, and restricts surgical procedures, eventually leading to a healthy and improved quality of life for elderly individuals.

  • As per the statistics presented by CDC data, around 49.5%, which means nearly half of the population aged 65 years or older, has been affected by major bone-related concerns like osteoarthritis by medical professionals.

Restraint: High-cost and alternative treatment options

The major restraining factors of the viscosupplementation market are the high cost of supplements and the number of alternative treatments available in the market to compete with. Alternative treatments such as physical therapies and oral medications treatment can become a barrier for the market, including the relatively higher costs for viscosupplementation, especially for individuals from underprivileged regions with low economic backgrounds.

Oral medications like analgesics are frequently used by people to deal with pain induced by osteoarthritis. As it is an instantaneous relief provided by analgesics and other pain-reducing tablets, they could hinder market expansion further. Along with this, physiotherapy is another branch of therapy that deals with specific types of massages and targets points in the body to relax muscles and areas of pain. Many people prefer these techniques due to their effect and the relaxing feel provided by skilled ones. Physical therapy is, again, a non-invasive process and relatively more budget-friendly than viscosupplements on the market.

Furthermore, the higher cost of viscosupplementation, in particular, while taking multiple sessions of it, becomes over budgetary for those without comprehensive insurance coverage. Along with this, stringent regulations and procedures to approve viscosupplements can create significant barriers in the market as they are compelled with complex rules and a long time for approval and time use of such supplements. Hence, these are some of the considerable limitations that the viscosupplementation market is dealing with, and they further deter its expansion on the global level if it is not overcome by major key holders in the market.

Opportunity: Innovative formulations

A major future opportunity that holds the potential to further propel the viscosupplementation market on a wider scale is innovations in new launch products and their formulations to create more effective results or outcomes in patients suffering from a particular kind of physical discomfort or disease particularly related to bones. Several factors can create opportunities in the market. One of them is innovations in hyaluronic acid formulations, which is a key component of the treatment. Developing next-generation HA products with increasing density and viscosity and long-term effects can improve patients' health.

  • In May 2022, Fidia Farmaceutici SPA successfully harnessed the regenerative capacity of the HA with its innovative portfolio, which was launched in Spain.

Advances in personalized medications also create opportunities for viscosupplements, which could lead to tailored supplements based on the personalized needs of patients and their responses, enhancing satisfaction and efficacy. To achieve this, a partnership between healthcare providers, biotech firms, and research institutes plays a key role in developing such customized solutions and bringing new, effective products of viscosupplements to help grow the market exponentially on a global level.

Moreover, the integration of the healthcare sector with advanced imaging and techniques regarding injectables in the context of treatment for osteoarthritis makes it a more attractive alternative for both patients and medical professionals. Also, the rising adoption of preventive care can become the focus of treatment, thus leading to a viscosupplementation as an early-based prevention method to avoid non-surgical procedures. Therefore, advances in medications, integration of healthcare into technology, and increasing adoption of preventive care can create huge opportunities in the viscosupplementation market and drive the market globally.

Product Insights

Three major types of products are available in the market: single injection, three injections, and five injections. By product, the three-injection segment dominated the viscosupplementation market in 2023. The three-injection procedure is the most followed by practitioners to treat osteoarthritis as it has immensely productive outcomes and is effective in tackling arthritis-related uneasiness. Due to such efficacy in the result, this method aids in avoiding surgical intervention such as total knee replacement, which is not preferable by a number of patients and professionals, as well as creating a mobility barrier in the patients and restricting their movement to a greater extent.

Also, several clinical trials have shown a positive aftereffect of the three injection methods, with lasting results and satisfaction noted by patients. Hence, the availability of three injections in the market is a major factor driving this segment, further leading to the expansion of the market.

The single injection segment is anticipated to showcase rising growth in the viscosupplementation market over the forecasted years. Although these single injections are newly launched in the market, they have shown promising results owing to the relatively lesser regimen, reducing visits to hospitals with lesser side effects and pain associated with it. For instance, Zimmer Biomet has launched its first low-volume viscosupplement, gel-one, within the range of a single injection formula. It is specifically tailored for patients who are not responding to conventional treatments, thereby strengthening its position and hold in the market.

End-use Insights

The viscosupplementation market is further divided into hospitals, orthopedic clinics, and ASCs. The orthopedic clinic/ASC segment dominated the market globally in 2023. The growth is attributed to the fact that the high demand for outpatient surgeries requires dedicated orthopedic clinics supported by the required equipment and skilled medical professionals. This is associated with surgical as well as non-surgical methods like joints, muscles, spine, and bone ligaments. The rising incidence of osteoarthritis among elderly people plays a crucial role in developing the growth of this segment. The segment is again fuelled by the fastest-growing rate of ambulatory surgical centers and their frequent use by professionals, as they can perform same-day surgeries for hip, knee, and other joint replacements. These surgeries are relatively less complex and do not require hospitalization; hence, they are preferred by patients as well, and they provide time flexibility and convenience.

Viscosupplementation Market Share, By End-use, 2023 (%)

Despite the orthopedic clinic’s dominance, the hospital segment is forecasted to grow rapidly in the market owing to the advancements in technology and services provided in hospitals. According to recent data, the number of patients dealing with arthritis is growing with each passing year due to the shifting in the older demographics across the globe. Such a staggering number needs to be looked after and resolved.

Viscosupplementation Market Recent Developments

  • In November 2022, Anika Therapeutics Inc., a leading joint preservation healthcare firm, successfully completed the phase-3 study for a single primary endpoint. This medication is particularly curated for those dealing with severe knee osteoarthritis. This enterprise is further focusing on achieving FDA approval for its medication and its clearance to use in the global market.
  • In June 2022, Johnson and Johnson released new data from phase-3 trials showing patients treated with medications who have achieved better and more consistent long-term results through two years of dealing with active psoriatic arthritis.

Viscosupplementation Market Companies

  • DePuy Synthes
  • Fidia Farmaceutici S.p.A
  • Sanofi
  • Smith & Nephew PLC
  • Anika Therapeutics, Inc.
  • Seikagaku Corp.
  • Zimmer Biomet
  • Ferring Pharmaceuticals B.V.
  • Lifecore Biomedical
  • LG Life Sciences Ltd.
  • F.Hoffmann-La Roche Ltd.

Segments Covered in the Report

By Product

  • Single Injection
  • Three Injection
  • Five Injection

By End-use

  • Hospitals
  • Orthopaedic Clinics/ASCs

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

How big is the viscosupplementation industry?
The global viscosupplementation market size is expected to increase USD 12.10 billion by 2033 from USD 4.84 billion in 2023.
What is the growth rate of the viscosupplementation industry?
The global viscosupplementation market will register growth rate of 9.60% between 2024 and 2033.
Who are the prominent players operating in the viscosupplementation market?
The major players operating in the viscosupplementation market are DePuy Synthes, Fidia Farmaceutici S.p.A, Sanofi, Smith & Nephew PLC, Anika Therapeutics, Inc., Seikagaku Corp., Zimmer Biomet, Ferring Pharmaceuticals B.V., Lifecore Biomedical, LG Life Sciences Ltd., F.Hoffmann-La Roche Ltd., and Others.
Which are the driving factors of the viscosupplementation market?
The driving factors of the viscosupplementation market are the growing inclination towards non-surgical interventions and development of new and improved hyaluronic acid formulations.
Which region will lead the global viscosupplementation market?
Asia Pacific region will lead the global viscosupplementation market during the forecast period 2024 to 2033.

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample